For the millions of people who have spent years struggling to swallow food, choking at meals, or undergoing repeated endoscopies without a clear diagnosis, the arrival of biologic therapies for eosinophilic esophagitis represents a genuine turning point. Dupixent (dupilumab), the first and only FDA-approved biologic for EoE, has been available for adults and adolescents since May 2022 and was expanded in January 2024 to children as young as one year old — making it the first approved EoE treatment for that age group. Meanwhile, cendakimab, developed by Bristol Myers Squibb, posted positive Phase 3 results published in NEJM Evidence in October 2025, and could become the second biologic to reach the market. A third candidate, tezepelumab, is currently in Phase 3 trials with a novel mechanism that targets the disease further upstream than any existing therapy. This matters beyond gastroenterology. EoE is an immune-mediated condition driven by the same type 2 inflammatory pathways implicated in asthma, eczema, and allergic rhinitis — and roughly 75 percent of EoE patients have at least one of these atopic conditions. For readers of this site who follow developments in neuroimmunology and brain health, the broader lesson is instructive: chronic inflammatory conditions that were once dismissed or misdiagnosed are now yielding to targeted biologic therapies, and the pace of that progress is accelerating.
This article walks through the disease itself, the biologics currently approved and in development, cost and access realities, and what the expanding EoE treatment landscape signals for immune-mediated diseases more broadly. Consider someone like a 34-year-old teacher who spent eight years — close to the documented mean diagnostic delay for adults — assuming her difficulty swallowing was just acid reflux. She avoided steak, ate slowly, drank water with every bite, and was told repeatedly that her symptoms were GERD. By the time she received a correct EoE diagnosis, her esophagus had developed fibrous strictures. Her story is not unusual. It is, in many ways, the standard EoE experience. The therapies discussed here are changing that trajectory, but only if patients and clinicians know they exist.
Table of Contents
- What Is Eosinophilic Esophagitis and Why Is It Only Now Getting Serious Attention?
- Dupixent — What the First Approved Biologic Does and Where It Falls Short
- Cendakimab — The Leading Challenger With Phase 3 Data in Hand
- Tezepelumab and the Case for Targeting EoE Further Upstream
- The Biologics That Have Not Lived Up to Expectations
- What EoE Treatment Costs and What That Means for Patient Access
- What the EoE Story Tells Us About the Future of Immune-Mediated Disease
- Conclusion
- Frequently Asked Questions
What Is Eosinophilic Esophagitis and Why Is It Only Now Getting Serious Attention?
Eosinophilic esophagitis is a chronic, immune-mediated disease in which eosinophils — a type of white blood cell normally involved in fighting parasites — accumulate in the lining of the esophagus, causing inflammation, swelling, and over time, scarring and narrowing. It is now recognized as the leading cause of dysphagia and food impaction in children and young adults. EoE affects approximately 1 in 700 people in the United States, with a prevalence rate of roughly 147.4 per 100,000 individuals. Among those under 65, the prevalence reached 1 in 617 by 2022. These are not rare numbers. this is a disease hiding in plain sight. The reason it went unrecognized for so long is partly behavioral. patients unconsciously adapt. They chew excessively, avoid certain textures, drink large amounts of liquid with meals, and eat more slowly than anyone around them. Many have done this since childhood and assume it is normal. Clinicians, meanwhile, frequently attribute the symptoms to gastroesophageal reflux disease, which looks similar on the surface but involves entirely different pathology.
The mean diagnostic delay is approximately 3.5 years in children and stretches to 8 years in adults. During that delay, chronic inflammation silently remodels the esophagus. The shift in attention has been driven by two forces: epidemiology and pharmacology. Prevalence has increased five-fold since 2009, with the highest rates in North America, males, and high-income countries. Global pooled incidence now stands at 5.31 per 100,000 inhabitant-years. Annual U.S. healthcare costs for EoE were estimated at $1.3 billion in 2024 dollars. A disease that costs that much and affects that many people eventually attracts pharmaceutical investment. Before 2022, there were zero FDA-approved treatments specifically for EoE. Patients relied on off-label proton pump inhibitors, topical corticosteroids adapted from asthma inhalers, and restrictive elimination diets. The landscape has changed remarkably fast.
Dupixent — What the First Approved Biologic Does and Where It Falls Short
Dupixent (dupilumab), manufactured by Sanofi and Regeneron, works by blocking interleukin-4 and interleukin-13 signaling through the IL-4 receptor alpha subunit. These two cytokines are central drivers of type 2 inflammation, the same immune pathway behind atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps — conditions for which Dupixent was already approved before it reached EoE. Its FDA approval for EoE came in May 2022 for adults and adolescents aged 12 and older weighing at least 40 kilograms. In January 2024, the indication was expanded to children aged 1 to 11 years weighing at least 15 kilograms, based on a pediatric trial in which 66 percent of children on Dupixent achieved histological remission — defined as six or fewer eosinophils per high-power field — at 16 weeks, compared to just 3 percent on placebo. Those numbers are difficult to argue with. However, Dupixent is not without significant limitations. The list price runs approximately $3,803 per carton, translating to an annual cost of roughly $35,000 to $40,000 per patient.
Sanofi offers a $0 copay card covering up to $13,000 per year for commercially insured patients, but that still leaves substantial cost exposure for many families, and patients on government insurance programs may face different barriers entirely. The drug requires ongoing subcutaneous injections — it is not a cure, and discontinuation typically leads to disease recurrence. Some patients also experience injection-site reactions, conjunctivitis, or other side effects already documented in its use for atopic dermatitis. There is another practical consideration: Dupixent addresses the inflammatory component of EoE but does not reverse existing fibrotic damage. A patient diagnosed after years of uncontrolled inflammation may still need esophageal dilation procedures even after starting biologic therapy. This is why early diagnosis matters so much — biologics are most transformative when they prevent structural damage rather than attempt to manage its consequences. If you or a family member has symptoms consistent with EoE, waiting years for a correct diagnosis is not a neutral act. It has physical consequences that no drug can fully undo.
Cendakimab — The Leading Challenger With Phase 3 Data in Hand
Cendakimab, developed by Bristol Myers Squibb, targets interleukin-13 specifically rather than blocking both IL-4 and IL-13 as Dupixent does. This more selective approach has theoretical appeal: IL-13 is considered the dominant cytokine driving esophageal eosinophilia and tissue remodeling, so targeting it directly could offer a cleaner pharmacological profile. The Phase 3 trial results, published in NEJM Evidence in October 2025, enrolled 430 patients aged 12 to 75 with confirmed EoE and randomized them to cendakimab 360 milligrams weekly or placebo for 48 weeks. The headline numbers were encouraging. At week 24, patients on cendakimab experienced a reduction of 6.3 dysphagia days compared to 4.7 days for placebo, a statistically significant difference. Histologic response — the critical measure of whether eosinophils are actually being cleared from esophageal tissue — was 29.5 percent for cendakimab versus 2.1 percent for placebo.
That gap is meaningful, though it is worth noting that the histologic response rate is lower than what Dupixent demonstrated in its pivotal trials. Direct cross-trial comparisons are unreliable due to differences in patient populations, endpoints, and study design, but the numbers will inevitably be placed side by side when clinicians and payers make formulary decisions. The side-effect profile was not dose-limiting, and cendakimab also showed significant improvement in endoscopic features of the disease. Bristol Myers Squibb is preparing a commercial autoinjector formulation, though an FDA submission timeline has not been publicly announced. If approved, cendakimab would become the second biologic available for EoE, introducing competition that could improve access, drive negotiation on pricing, and offer an alternative mechanism for patients who do not respond adequately to Dupixent. For a disease that had zero approved therapies four years ago, having two distinct biologic options would represent a remarkable shift.
Tezepelumab and the Case for Targeting EoE Further Upstream
While Dupixent and cendakimab both operate at the cytokine level — blocking IL-4, IL-13, or both — tezepelumab takes a fundamentally different approach. Developed by AstraZeneca and Amgen, tezepelumab is a first-in-class monoclonal antibody that targets thymic stromal lymphopoietin, or TSLP, an epithelial cytokine released by the esophageal lining in response to allergens and other triggers. TSLP acts upstream of IL-4 and IL-13, initiating the inflammatory cascade before those downstream cytokines are even produced. In theory, blocking the signal at its origin could provide broader suppression of the type 2 immune response driving EoE. Tezepelumab was granted FDA Orphan Drug Designation for EoE in 2021 and is already approved for severe asthma under the brand name Tezspire, as well as for chronic rhinosinusitis with nasal polyps as of 2025.
The Phase 3 CROSSING trial, a randomized, double-blind, placebo-controlled study, is currently ongoing with approximately 360 adult and adolescent EoE patients, a 52-week treatment period, and an optional 24-week extension. Results are not yet available, but the trial design is robust and the drug’s established safety profile from other indications provides a baseline of confidence. The tradeoff with upstream targeting is uncertainty about specificity. Blocking TSLP suppresses a broader swath of immune activity than blocking a single downstream cytokine, which could mean greater efficacy in some patients — particularly those with multiple atopic conditions — but could also carry different safety implications. For EoE patients who also have severe asthma or nasal polyps, a single biologic addressing multiple conditions simultaneously would be a significant practical advantage, reducing injection burden and potentially simplifying insurance negotiations. Whether tezepelumab actually delivers on that theoretical promise in EoE specifically remains to be seen, pending the CROSSING trial results.
The Biologics That Have Not Lived Up to Expectations
Not every biologic targeting eosinophilic esophagitis has succeeded, and the failures are as instructive as the successes. Mepolizumab and reslizumab, both anti-IL-5 antibodies, were investigated for EoE based on a straightforward hypothesis: since eosinophils are the hallmark cell in EoE, and IL-5 is the primary survival factor for eosinophils, blocking IL-5 should resolve the disease. The logic was clean. The results were not. Both drugs reduced eosinophil counts in esophageal tissue but failed to produce meaningful symptom improvement. Patients still had difficulty swallowing. This disconnect forced researchers to reckon with an uncomfortable reality: eosinophil counts alone do not fully explain the symptoms of EoE. Tissue remodeling, mast cell activity, and other inflammatory mediators all contribute to the clinical picture.
Benralizumab, which targets the IL-5 receptor alpha subunit and thereby depletes eosinophils more completely than anti-IL-5 antibodies, has shown a similar pattern — effective eosinophil reduction without corresponding symptom relief. Lirentelimab, which targets Siglec-8 on both eosinophils and mast cells, represents an attempt to address the mast cell component of EoE pathology, but clinical data remain early-stage. Dectrekumab, another anti-IL-13 antibody, is in earlier investigation and its differentiation from cendakimab is not yet clear. The warning here is against assuming that any biologic in the pipeline will necessarily work. The history of EoE drug development includes more setbacks than victories. Patients and families following this space should be cautious about preliminary announcements and Phase 2 data, which often do not replicate in larger trials. The drugs that have succeeded — Dupixent definitively, cendakimab promisingly — did so by targeting pathways involved in tissue remodeling and symptom generation, not just eosinophil survival. That distinction has reshaped how researchers think about what EoE actually is.
What EoE Treatment Costs and What That Means for Patient Access
The economic reality of biologic therapy for EoE is stark. At $35,000 to $40,000 per year for Dupixent, long-term treatment represents a significant financial commitment even with insurance coverage. Sanofi’s $0 copay card, covering up to $13,000 per year, applies only to commercially insured patients and does not extend to those on Medicare, Medicaid, or other government programs. Prior authorization requirements are common, and insurers may require documentation of failed conventional therapies — proton pump inhibitors, swallowed topical corticosteroids, elimination diets — before approving biologic coverage. For a patient who has already spent years being misdiagnosed, the additional months required to satisfy step-therapy protocols can feel punitive.
The arrival of a second approved biologic, if cendakimab reaches the market, would be significant not only clinically but economically. Competition tends to moderate pricing, improve copay assistance programs, and give insurance companies less leverage to deny coverage when an alternative exists. The total annual U.S. healthcare cost burden for EoE — estimated at $1.3 billion — includes emergency department visits for food impaction, repeated endoscopies, and lost productivity, costs that effective biologic therapy could substantially reduce. But that reduction only materializes if patients can actually access the drugs, and right now, access remains unevenly distributed by insurance type, geography, and the availability of gastroenterologists experienced with EoE.
What the EoE Story Tells Us About the Future of Immune-Mediated Disease
The trajectory of eosinophilic esophagitis — from an unrecognized condition to a billion-dollar treatment market in under two decades — offers a template for how medicine is likely to handle other immune-mediated diseases going forward. The pattern is becoming familiar: a condition is identified, its immune mechanism is characterized, existing biologics developed for related conditions are tested against it, and within a few years the treatment landscape transforms. Dupixent followed exactly this path, moving from atopic dermatitis to asthma to nasal polyps to EoE. Tezepelumab is following a similar trajectory from asthma to EoE to potentially other eosinophilic conditions. For readers interested in brain health and neuroinflammation, the parallel is worth watching.
Type 2 inflammation and eosinophilic activity are not confined to the esophagus, skin, and lungs. Research into neuroimmune interactions continues to expand, and the success of targeted biologics in conditions like EoE strengthens the broader case that precise immune modulation — rather than blunt immunosuppression — can meaningfully change disease outcomes. The next five years will likely bring additional EoE approvals, longer-term safety data, and a clearer understanding of which patients benefit most from which biologic approach. For a condition that had no approved therapy before 2022, that pace of progress is extraordinary, and it did not happen by accident. It happened because patients demanded answers and researchers finally listened.
Conclusion
Eosinophilic esophagitis has moved from diagnostic obscurity to an active, competitive biologic treatment landscape in remarkably short order. Dupixent remains the only approved biologic, now available for patients as young as one year old, with strong histologic remission data and expanding real-world evidence. Cendakimab has posted positive Phase 3 results that position it as the leading challenger, while tezepelumab’s upstream mechanism offers a genuinely novel approach currently being tested in a large Phase 3 trial. The failures of anti-IL-5 therapies have clarified that EoE is more than an eosinophil-counting exercise, reshaping both research priorities and clinical thinking.
For patients and families navigating EoE, the practical takeaway is that options exist now that did not exist four years ago, and more are likely coming. The persistent challenges — diagnostic delays averaging up to eight years in adults, annual treatment costs in the tens of thousands of dollars, and uneven insurance coverage — remain real and should not be minimized. But the direction of travel is clear. If you suspect you or someone you care for may have EoE, the single most important step is obtaining an accurate diagnosis through endoscopy with biopsy, because every year of uncontrolled inflammation carries consequences that even the best biologic cannot fully reverse.
Frequently Asked Questions
What is the only FDA-approved biologic for eosinophilic esophagitis?
Dupixent (dupilumab), manufactured by Sanofi and Regeneron, is currently the only biologic approved by both the FDA and EMA for EoE. It was first approved in May 2022 for patients aged 12 and older and expanded in January 2024 to include children as young as one year old weighing at least 15 kilograms.
How much does Dupixent cost for EoE treatment?
The list price is approximately $3,803 per carton, translating to roughly $35,000 to $40,000 per year. Sanofi offers a $0 copay card covering up to $13,000 annually for commercially insured patients, but coverage varies significantly by insurance type and prior authorization requirements are common.
What is cendakimab and when might it be approved?
Cendakimab is an anti-IL-13 biologic developed by Bristol Myers Squibb that showed positive Phase 3 results published in NEJM Evidence in October 2025. In trials, 29.5 percent of patients achieved histologic response versus 2.1 percent on placebo. An FDA submission timeline has not been publicly announced, but BMS is preparing a commercial autoinjector formulation.
Why did anti-IL-5 biologics fail for EoE?
Mepolizumab, reslizumab, and benralizumab all successfully reduced eosinophil counts in esophageal tissue but failed to produce meaningful symptom improvement. This revealed that EoE symptoms are driven not only by eosinophils but also by tissue remodeling, mast cell activity, and other inflammatory mediators that anti-IL-5 agents do not address.
How long does it typically take to get an EoE diagnosis?
The mean diagnostic delay is approximately 3.5 years in children and up to 8 years in adults. Many patients unknowingly compensate by eating slowly, avoiding certain food textures, and drinking excessive fluids with meals. EoE is frequently misdiagnosed as GERD, which delays appropriate treatment and allows ongoing esophageal damage.
Is there a connection between EoE and other allergic conditions?
Yes. Approximately 75 percent of EoE patients have at least one atopic condition, including food allergies, eczema, asthma, or allergic rhinitis. EoE is driven by type 2 inflammation, the same immune pathway underlying these related allergic diseases, which is why biologics developed for atopic conditions are now being tested and approved for EoE.
